vs
Idexx Laboratories（IDXX）与Roper Technologies（ROP）财务数据对比。点击上方公司名可切换其他公司
Roper Technologies的季度营收约是Idexx Laboratories的1.9倍（$2.1B vs $1.1B），Idexx Laboratories净利率更高（22.8% vs 15.8%，领先7.0%），Idexx Laboratories同比增速更快（14.3% vs 11.3%），Roper Technologies自由现金流更多（$507.0M vs $326.3M），过去两年Roper Technologies的营收复合增速更高（10.5% vs 6.4%）
IDEXX Laboratories是1983年成立的美国跨国企业，主营伴侣动物诊疗、畜禽养殖、水质检测、乳制品领域相关产品与服务的研发、生产及分销，总部位于缅因州韦斯特布鲁克，欧洲、中东及非洲地区分部设于荷兰霍夫多普。
罗珀技术公司是一家专注于科技领域的控股企业，通过持有并运营多家不同细分赛道的科技公司，在科技产业投资与资产管理领域形成了成熟的业务体系，在全球相关市场具备较高的行业影响力。
IDXX vs ROP — 直观对比
营收规模更大
ROP
是对方的1.9倍
$1.1B
营收增速更快
IDXX
高出3.0%
11.3%
净利率更高
IDXX
高出7.0%
15.8%
自由现金流更多
ROP
多$180.7M
$326.3M
两年增速更快
ROP
近两年复合增速
6.4%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $2.1B |
| 净利润 | $248.2M | $331.0M |
| 毛利率 | 60.3% | 69.4% |
| 营业利润率 | 28.9% | 27.2% |
| 净利率 | 22.8% | 15.8% |
| 营收同比 | 14.3% | 11.3% |
| 净利润同比 | 14.8% | 53.7% |
| 每股收益（稀释后） | $3.09 | $4.87 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IDXXROP
| Q1 26 | — | $2.1B | ||
| Q4 25 | $1.1B | $2.1B | ||
| Q3 25 | $1.1B | $2.0B | ||
| Q2 25 | $1.1B | $1.9B | ||
| Q1 25 | $998.4M | $1.9B | ||
| Q4 24 | $954.3M | $1.9B | ||
| Q3 24 | $975.5M | $1.8B | ||
| Q2 24 | $1.0B | $1.7B |
净利润IDXXROP
| Q1 26 | — | $331.0M | ||
| Q4 25 | $248.2M | $428.4M | ||
| Q3 25 | $274.6M | $398.5M | ||
| Q2 25 | $294.0M | $378.3M | ||
| Q1 25 | $242.7M | $331.1M | ||
| Q4 24 | $216.1M | $462.3M | ||
| Q3 24 | $232.8M | $367.9M | ||
| Q2 24 | $203.3M | $337.1M |
毛利率IDXXROP
| Q1 26 | — | 69.4% | ||
| Q4 25 | 60.3% | 69.5% | ||
| Q3 25 | 61.8% | 69.5% | ||
| Q2 25 | 62.6% | 69.2% | ||
| Q1 25 | 62.4% | 68.7% | ||
| Q4 24 | 59.8% | 68.3% | ||
| Q3 24 | 61.1% | 69.2% | ||
| Q2 24 | 61.7% | 69.5% |
营业利润率IDXXROP
| Q1 26 | — | 27.2% | ||
| Q4 25 | 28.9% | 28.6% | ||
| Q3 25 | 32.1% | 28.4% | ||
| Q2 25 | 33.6% | 28.2% | ||
| Q1 25 | 31.7% | 27.9% | ||
| Q4 24 | 27.4% | 28.0% | ||
| Q3 24 | 31.2% | 28.1% | ||
| Q2 24 | 26.3% | 28.8% |
净利率IDXXROP
| Q1 26 | — | 15.8% | ||
| Q4 25 | 22.8% | 20.8% | ||
| Q3 25 | 24.8% | 19.8% | ||
| Q2 25 | 26.5% | 19.5% | ||
| Q1 25 | 24.3% | 17.6% | ||
| Q4 24 | 22.7% | 24.6% | ||
| Q3 24 | 23.9% | 20.8% | ||
| Q2 24 | 20.3% | 19.6% |
每股收益（稀释后）IDXXROP
| Q1 26 | — | $4.87 | ||
| Q4 25 | $3.09 | $3.97 | ||
| Q3 25 | $3.40 | $3.68 | ||
| Q2 25 | $3.63 | $3.49 | ||
| Q1 25 | $2.96 | $3.06 | ||
| Q4 24 | $2.62 | $4.29 | ||
| Q3 24 | $2.80 | $3.40 | ||
| Q2 24 | $2.44 | $3.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.1M | $382.9M |
| 总债务越低越好 | $450.0M | $9.7B |
| 股东权益账面价值 | $1.6B | $18.8B |
| 总资产 | $3.4B | $34.6B |
| 负债/权益比越低杠杆越低 | 0.28× | 0.52× |
8季度趋势，按日历期对齐
现金及短期投资IDXXROP
| Q1 26 | — | $382.9M | ||
| Q4 25 | $180.1M | $297.4M | ||
| Q3 25 | $208.2M | $320.0M | ||
| Q2 25 | $164.6M | $242.4M | ||
| Q1 25 | $164.0M | $372.8M | ||
| Q4 24 | $288.3M | $188.2M | ||
| Q3 24 | $308.6M | $269.6M | ||
| Q2 24 | $401.6M | $251.5M |
总债务IDXXROP
| Q1 26 | — | $9.7B | ||
| Q4 25 | $450.0M | $9.3B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $617.8M | $7.6B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益IDXXROP
| Q1 26 | — | $18.8B | ||
| Q4 25 | $1.6B | $19.9B | ||
| Q3 25 | $1.6B | $20.0B | ||
| Q2 25 | $1.5B | $19.6B | ||
| Q1 25 | $1.4B | $19.2B | ||
| Q4 24 | $1.6B | $18.9B | ||
| Q3 24 | $1.6B | $18.5B | ||
| Q2 24 | $1.6B | $18.1B |
总资产IDXXROP
| Q1 26 | — | $34.6B | ||
| Q4 25 | $3.4B | $34.6B | ||
| Q3 25 | $3.4B | $34.6B | ||
| Q2 25 | $3.3B | $33.2B | ||
| Q1 25 | $3.2B | $31.4B | ||
| Q4 24 | $3.3B | $31.3B | ||
| Q3 24 | $3.4B | $31.6B | ||
| Q2 24 | $3.4B | $29.8B |
负债/权益比IDXXROP
| Q1 26 | — | 0.52× | ||
| Q4 25 | 0.28× | 0.47× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.39× | 0.40× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $355.8M | — |
| 自由现金流经营现金流 - 资本支出 | $326.3M | $507.0M |
| 自由现金流率自由现金流/营收 | 29.9% | 24.2% |
| 资本支出强度资本支出/营收 | 2.7% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.43× | — |
| 过去12个月自由现金流最近4个季度 | $1.1B | — |
8季度趋势，按日历期对齐
经营现金流IDXXROP
| Q1 26 | — | — | ||
| Q4 25 | $355.8M | $738.0M | ||
| Q3 25 | $402.3M | $869.5M | ||
| Q2 25 | $185.7M | $404.1M | ||
| Q1 25 | $238.0M | $528.7M | ||
| Q4 24 | $262.0M | $722.2M | ||
| Q3 24 | $220.1M | $755.4M | ||
| Q2 24 | $248.3M | $384.1M |
自由现金流IDXXROP
| Q1 26 | — | $507.0M | ||
| Q4 25 | $326.3M | — | ||
| Q3 25 | $371.2M | — | ||
| Q2 25 | $151.6M | — | ||
| Q1 25 | $207.9M | — | ||
| Q4 24 | $232.8M | — | ||
| Q3 24 | $192.0M | — | ||
| Q2 24 | $215.0M | — |
自由现金流率IDXXROP
| Q1 26 | — | 24.2% | ||
| Q4 25 | 29.9% | — | ||
| Q3 25 | 33.6% | — | ||
| Q2 25 | 13.7% | — | ||
| Q1 25 | 20.8% | — | ||
| Q4 24 | 24.4% | — | ||
| Q3 24 | 19.7% | — | ||
| Q2 24 | 21.4% | — |
资本支出强度IDXXROP
| Q1 26 | — | 0.5% | ||
| Q4 25 | 2.7% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 3.1% | — | ||
| Q1 25 | 3.0% | — | ||
| Q4 24 | 3.1% | — | ||
| Q3 24 | 2.9% | — | ||
| Q2 24 | 3.3% | — |
现金转化率IDXXROP
| Q1 26 | — | — | ||
| Q4 25 | 1.43× | 1.72× | ||
| Q3 25 | 1.47× | 2.18× | ||
| Q2 25 | 0.63× | 1.07× | ||
| Q1 25 | 0.98× | 1.60× | ||
| Q4 24 | 1.21× | 1.56× | ||
| Q3 24 | 0.95× | 2.05× | ||
| Q2 24 | 1.22× | 1.14× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IDXX
| Vet Lab Consumables | $389.0M | 36% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32% |
| Rapid Assay Products | $76.0M | 7% |
| Recurring Revenue | $70.6M | 6% |
| CAG Diagnostic Capital Instruments | $58.1M | 5% |
| Water Segment | $50.5M | 5% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3% |
| CAG Diagnostics Service And Accessories | $35.3M | 3% |
| Systems And Hardware | $20.1M | 2% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0% |
ROP
暂无分部数据
